1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms
(
- Contribution to journal › Scientific review
-
Mark
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
- 2022
-
Mark
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
- 2021
-
Mark
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors
(
- Contribution to journal › Article
- 2017
-
Mark
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Scientific review